CEP72 and B-cell non-Hodgkin lymphoma: To our knowledge, this is the largest pharmacogenomics study to explore the association of CEP72 rs924607 and VIPN in adult patients with aggressive B-cell lymphoma receiving (R-)CHOP based immunochemotherapy in the context of a prospective randomized phase III trial.